Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Kristina Klupsch"'
Autor:
Anne E Roehrig, Kristina Klupsch, Juan A Oses-Prieto, Selim Chaib, Stephen Henderson, Warren Emmett, Lucy C Young, Silvia Surinova, Andreas Blees, Anett Pfeiffer, Maha Tijani, Fabian Brunk, Nicole Hartig, Marta Muñoz-Alegre, Alexander Hergovich, Barbara H Jennings, Alma L Burlingame, Pablo Rodriguez-Viciana
Publikováno v:
PLoS ONE, Vol 16, Iss 8, p e0254697 (2021)
The PAF complex (PAFC) coordinates transcription elongation and mRNA processing and its CDC73/parafibromin subunit functions as a tumour suppressor. The NF2/Merlin tumour suppressor functions both at the cell cortex and nucleus and is a key mediator
Externí odkaz:
https://doaj.org/article/060b7e02b03d49888281c2e401c2133d
Autor:
Ulrich Wuellner, Kristina Klupsch, Fabian Buller, Isabella Attinger-Toller, Roger Santimaria, Irene Zbinden, Patricia Henne, Dragan Grabulovski, Julian Bertschinger, Simon Brack
Publikováno v:
Antibodies, Vol 4, Iss 4, Pp 426-440 (2015)
CD3 bispecific therapies retargeting T cells to tumors have recently demonstrated striking activity in patients. Several CD3 bispecific antibodies directed against various tumor targets are currently being investigated in the clinic across different
Externí odkaz:
https://doaj.org/article/ace5b95010614b2c9dd9d0be87c5386d
Autor:
Alison Wood-Kaczmar, Sonia Gandhi, Zhi Yao, Andrey Y Abramov, Erik A Miljan, Gregory Keen, Lee Stanyer, Iain Hargreaves, Kristina Klupsch, Emma Deas, Julian Downward, Louise Mansfield, Parmjit Jat, Joanne Taylor, Simon Heales, Michael R Duchen, David Latchman, Sarah J Tabrizi, Nicholas W Wood
Publikováno v:
PLoS ONE, Vol 3, Iss 6, p e2455 (2008)
Parkinson's disease (PD) is a common age-related neurodegenerative disease and it is critical to develop models which recapitulate the pathogenic process including the effect of the ageing process. Although the pathogenesis of sporadic PD is unknown,
Externí odkaz:
https://doaj.org/article/e6f71b48d51e401d9ebca115efdfb402
Autor:
Alison Wood-Kaczmar, Sonia Gandhi, Zhi Yao, Andrey Y. Abramov, Erik A. Miljan, Gregory Keen, Lee Stanyer, Iain Hargreaves, Kristina Klupsch, Emma Deas, Julian Downward, Louise Mansfield, Parmjit Jat, Joanne Taylor, Simon Heales, Michael R. Duchen, David Latchman, Sarah J. Tabrizi, Nicholas W. Wood
Publikováno v:
PLoS ONE, Vol 3, Iss 8 (2008)
Externí odkaz:
https://doaj.org/article/ff67d02b2fbb499d991a78f5293df7d3
Autor:
Dragan Grabulovski, Julian Bertschinger, Susann Koenig-Friedrich, Ulrike von der Bey, Helen Hachemi, Richard Woods, Kristina Klupsch, Frédéric Mourlane, Babette Schade, Isabella Attinger-Toller, Simon Brack
Figure S1: Characterization of binding properties and thermal stability of Fynomer C12; Figure S2: Results of binding studies with C12-pertuzumab bispecific FynomAbs; Figure S3: Additional in vitro tumour growth inhibition studies with COVA208 on mor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445349d5cf47ac41747b45e01414c47a
https://doi.org/10.1158/1535-7163.22499650.v1
https://doi.org/10.1158/1535-7163.22499650.v1
Autor:
Dragan Grabulovski, Julian Bertschinger, Susann Koenig-Friedrich, Ulrike von der Bey, Helen Hachemi, Richard Woods, Kristina Klupsch, Frédéric Mourlane, Babette Schade, Isabella Attinger-Toller, Simon Brack
Upregulation of HER2 is a hallmark of 20% to 30% of invasive breast cancers, rendering this receptor an attractive target for cancer therapy. Although HER2-targeting agents have provided substantial clinical benefit as cancer therapeutics, there is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a59a7c0038b589652edf37cad4f9dd5f
https://doi.org/10.1158/1535-7163.c.6536209
https://doi.org/10.1158/1535-7163.c.6536209
Autor:
Alma L. Burlingame, Warren Emmett, Andreas Blees, Fabian Brunk, Silvia Surinova, Anne E. Roehrig, Marta Munoz-Alegre, Alexander Hergovich, Kristina Klupsch, Maha Tijani, Anett Pfeiffer, Juan A. Oses-Prieto, Stephen Henderson, Pablo Rodriguez-Viciana, Nicole Hartig, Selim Chaib, Barbara H. Jennings, Lucy C. Young
Publikováno v:
PloS one, vol 16, iss 8
PLoS ONE
PLoS ONE, Vol 16, Iss 8, p e0254697 (2021)
PLoS ONE
PLoS ONE, Vol 16, Iss 8, p e0254697 (2021)
The PAF complex (PAFC) coordinates transcription elongation and mRNA processing and its CDC73/parafibromin subunit functions as a tumour suppressor. The NF2/Merlin tumour suppressor functions both at the cell cortex and nucleus and is a key mediator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230e0538a32a3dbbdd2c44b48de833dd
https://escholarship.org/uc/item/57d9s6th
https://escholarship.org/uc/item/57d9s6th
Autor:
Roland B. Walter, Roger Santimaria, Elena Kage, Wibke Lembke, Roland Scholz, Joana Dannenberg, Adrian Zumsteg, Dorina Saro, Lucijana Dinkel, Isabella Attinger-Toller, David Senn, Vanessa Baeriswyl, Ulrike Von Der Bey, Simon Brack, George S. Laszlo, Susann König-Friedrich, Kristina Klupsch, Fanny Dupuy, Julian Bertschinger, Severin Wendelspiess, Robert Hepler, Clara Albani, Chelsea J. Gudgeon
Publikováno v:
Leukemia. 33:805-808
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0616cc453616be097aec75d69a6737a
https://doi.org/10.1038/s41375-018-0249-z
https://doi.org/10.1038/s41375-018-0249-z
Autor:
Kristina, Klupsch, Vanessa, Baeriswyl, Roland, Scholz, Joana, Dannenberg, Roger, Santimaria, David, Senn, Elena, Kage, Adrian, Zumsteg, Isabella, Attinger-Toller, Ulrike, von der Bey, Susann, König-Friedrich, Fanny, Dupuy, Wibke, Lembke, Clara, Albani, Severin, Wendelspiess, Lucijana, Dinkel, Dorina, Saro, Robert W, Hepler, George S, Laszlo, Chelsea J, Gudgeon, Julian, Bertschinger, Simon, Brack, Roland B, Walter
Publikováno v:
Leukemia. 33(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e669a971a6efc24c91bb9abc3279e0b9
https://pubmed.ncbi.nlm.nih.gov/30206306
https://pubmed.ncbi.nlm.nih.gov/30206306
Autor:
Susann Koenig-Friedrich, Babette Schade, Richard Woods, Ulrike Von Der Bey, Julian Bertschinger, Simon Brack, Dragan Grabulovski, Isabella Attinger-Toller, Helen Hachemi, Frédéric Mourlane, Kristina Klupsch
Publikováno v:
Molecular Cancer Therapeutics. 13:2030-2039
Upregulation of HER2 is a hallmark of 20% to 30% of invasive breast cancers, rendering this receptor an attractive target for cancer therapy. Although HER2-targeting agents have provided substantial clinical benefit as cancer therapeutics, there is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d042035a188f62f2411f8877733b07
https://doi.org/10.1158/1535-7163.mct-14-0046-t
https://doi.org/10.1158/1535-7163.mct-14-0046-t